

CURRICULUM VITAE

NAME ILYA TSIMAFEYEU
SEX MALE
DATE OF BIRTH February 8, 1980



CURRENT POSITIONS

Director, Bureau for Cancer Research, USA / Russia
2007 – pres.

CEO, ILTIMO Inc.
2023 – pres.

Medical Oncologist & Scientific coordinator,
International Telehealth Cancer Center “STOONCO – Science & Technology in
Oncology”
2023 – pres.

PREVIOUS POSITION

Director, Institute of Oncology, Hadassah Medical
Moscow (branch of the Hadassah Medical Israel in
Moscow International Medical Cluster Skolkovo), RU;
2020-2021

Director, Russian Society of Clinical Oncology
(RUSSCO), RU; 2011-2019

ADVISORY ROLE

YEARS	DESCRIPTION	POSITION
2022-2025	Central and Eastern Europe Regional Council, American Society of Clinical Oncology - ASCO (USA)	Council Member
2021 – pres.	College of the European School of Oncology (EU)	Faculty Member
2018- pres.	Journal “Kidney Cancer”	Editorial Board Member
2021-2024	International Education Steering Group, American Society of Clinical Oncology - ASCO (USA)	Group Member
2011-2020	Board, Russian Society of Clinical Oncology (RU)	Member
2017-2019	IDEA Award working group, American Society of Clinical Oncology - ASCO (USA)	Group Member
2007–2018	Medical and Scientific Advisory Board, Kidney Cancer Association (USA)	Board Member
2009–2013	Clinical Trials Subcommittee, Kidney Cancer Association (USA)	Member
2010-2011	Kidney Cancer Patient League, Russia-Belarus-Ukraine	Past-President
2008-2010	Kidney Cancer Patient League, Russia-Belarus-Ukraine	President

EDUCATION

YEAR	DESCRIPTION	DEGREE OBTAINED
1997-2003	I.M. Sechenov Moscow Medical Academy	M.D. (General Medicine) with honors
2003 – 2006	Department of Oncology, I.M. Sechenov Moscow Medical Academy at N.N. Blokhin Cancer Research Center (Moscow)	Post-graduate training Medical Oncologist
2003 – 2007	Ph.D. thesis “Cytokines in the treatment of renal cell carcinoma and skin melanoma”	Ph.D.

CONTINUING MEDICAL EDUCATION

2008 – Oregon Health & Science University (Portland, USA)

2008 – Innovaacom Program “Mastering the How of Effective Medical Writing and Presenting”
(Moscow, Russia)

2006 – Clinique de Genolier (Geneva, Switzerland), CHUV (Switzerland, Lausanne)

2006 – Workshop on Methods in Clinical Cancer Research – FECS, AACR, ASCO (Flims, Switzerland)

2006 – American Cancer Society University (Washington, USA)

2006 – Ersta Hospice (Stockholm, Sweden)

MEMBERSHIPS

Active member, American Society of Clinical Oncology (ASCO)

Active member, American Association for Cancer Research (AACR)

Full Member, Flims Alumni Club

Full member, European Society of Medical Oncology (ESMO)

Member, Russian Society of Clinical Oncology (RUSSCO)

AWARDS & ACHIEVEMENTS

Most viewed paper 2023	Recipient	2024	Oncology Reviews journal (Frontiers Publishing)
EMUC (ESMO-EAU-ESTRO) 2023, HIGHLY RATED ABSTRACT AWARD	Recipient	2023	Marseille, France
International Kidney Cancer Symposium 2022, Selected Poster for the Poster Walk & Discussion	Presenter	2022	Austin, TX, USA
GI ASCO 2022, Selected Poster for the Poster Walk & Discussion	Presenter	2022	San Francisco, USA
Paper 2018-2019 (TOP 10% most downloaded papers)	Recipient	2020	British Journal of Urology International (Wiley)

First poster in track, AACR Special Conference on Tumor Immunology and Immunotherapy	Presenter	2019	Boston, USA
ENDO 2019, Late-breaking abstract, Gold ribbon	Recipient	2019	New Orlean, USA
MASCC 2018, Late-breaking abstract	Presenter	2018	Vienna, Austria
ASCO MERIT AWARD	Recipient	2016	San Francisco, USA
TOP Poster GU ASCO 2016	Presenter	2016	San Francisco, USA
100 Best Russian Inventions 2013	Recipient	2014	Moscow, RU
Prix Galien Russia 2013 "Best Research in Russia" for compound OM-RCA-01	Nominee	2013	Moscow, RU
EMUC-2013 (EAU-ESMO-ESTRO) First Prize for Best Oral Presentation	Recipient	2013	Marseille, France
Oncology Forum 2012 Grand prix; Top poster	Recipient	2012	Budapest, Hungary
AACR-AstraZeneca Scholar- in-Training Award	Recipient	2010	AACR-JCA, Hawaii, USA
Zvorykin' project, Innovative Russia "Gold Hundred"	Winner	2009	Moscow, RU
IDEA ASCO Award	Recipient	2008	ASCO, Chicago, USA
Best Innovation Scientific Project Award	Recipient	2007	Moscow, RU
ESMO Best Poster Award	Recipient	2007	ECLU, Switzerland
AACR-Aflac Award	Recipient	2007	AACR-JCA, Hawaii, USA
Certificate of Achievement for dedication and commitment to the global cancer control mission	Recipient	2006	American Cancer Society, Washington, DC, USA
First Award	Recipient	2003	IV Conference of Young Oncologists in Ukraine, Kiev, Ukraine
N.I. Pirogov Gold Medal for best junior investigation in Russia	Recipient	2003	Russian Academy of Medical Sciences, Moscow, RU
Certificate for outstanding achievements in tumor immunology	Recipient	2002	All-Russian program for the promotion of Higher Education, Moscow, RU

DRUG DISCOVERY AND R&D

Compound / Drug / Technology	Involvement	Year of project start	Present status
Novel technology of generation of fully human monoclonal antibodies	Author (patent application: USA)	2015	Development with Ilgen Inc (USA)
Allosteric inhibitor of Fibroblast Growth Factor Receptor 2 (RPT835; alofanib)	Author (patents: Russia and C.I.S; PCT (USA, Europe, China, Japan)	2011	Assignment of patent rights to pharmaceutical company (2013)
Novel Humanized Monoclonal Antibody Targeting Fibroblast Growth Factor Receptor 1 (now OM-RCA-01)	Author (patents: USA, Germany, Russia and C.I.S;)	2009	Assignment of patent rights to venture fund (2010)
Human fused protein bFGF-FGFR1	Author (patents: Russia and C.I.S)	2009	Terminated (2010)

PATENTS AND APPLICATIONS

Year	Patent/Application	Title
2009	EAPO patent 020171	Fused protein containing fibroblast growth factor and part of fibroblast growth factor receptor for the treatment of vascular diseases
2009	EAPO patent 016172	Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms
2009	US patent US 8487083	Monoclonal antibodies capable of simultaneously binding domains II and IIIc of type 1 fibroblast growth factor receptor
2011	Russian patent 2440142	Antibody for tumor growth delay
2012	EAPO patent 023383	Method for treatment of disease based on selective inhibition of parts of receptors of tyrosine kinases
2014	US application 15/355,506 JP application 2017-513314 EPO application 14892456.6 Chinese patent office application 14892456.6 EAPO application 201400495	Selective inhibitors interfering with fibroblast growth factor receptor and FRS2 interaction for the prevention and treatment of cancer and other diseases
2015	US application 14/819500	Identification of fully human antibodies for use in therapy and diagnosis of human diseases
2016	EAPO application	Method of preparation of inhibitors interfering with fibroblast

	201600017/26	growth factor receptor and FRS2 interaction
--	--------------	---

INTERNATIONAL CONFERENCES & CME COURSES ATTENDED WITH PRESENTATIONS

* - Speaker (Oral presentation)

^P - Presenting author (Poster presentation)

2003* – III Workshop of WHO collaborating center for gastric cancer, N.N. Blokhin Russian Cancer Research Center, Moscow
2003 – “Advances in lung cancer” European School of Oncology (Red Square Seminar), Moscow
2003* – IV Conference of Young Oncologists in Ukraine, Kiev, Ukraine
2004 – Genitourinary Cancer Conference, Russian-American Alliance, Moscow
2004* – III C.I.S. Cancer Congress, Minsk, Belarus
2005 – Skin Melanoma, European School of Oncology (Red Square Seminar), Moscow
2005* – Immunology for Oncologists, Advanced ESO Course, Ascona, Switzerland
2005 – Moscow Brest Cancer Forum, ESO, Moscow
2005 – Molecular and Genetic Diagnostics of Human Cancer, International Symposium, Moscow
2006 – American-Russian conference “Prevention and treatment of Tobacco-related cancers”, Moscow
2006* – 21st Annual Congress, European Association of Urology, Paris, France
2006* – European School of Oncology, Infections and Supportive therapy in Oncology, Conference, Moscow
2006* – World Cancer Congress, UICC, Washington, USA
2006* – “Oncology today”, Conference, Kazan, Russia
2006 – Palliative Cancer Care, ESO Advanced Course with 7-days residency in Ersta Hospice, Stockholm, Sweden
2006^P – The Fifth International Kidney Cancer Symposium, Chicago, USA
2006* – IV C.I.S. Cancer Congress, Baku, Azerbaijan
2007^P – 7th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association, Hawaii, USA
2007* – Second European Kidney Cancer Symposium, Rome, Italy
2007^P – 10th Congress of European Association for Palliative Care, Budapest, Hungary
2007^P – ESMO Conference Lugano, Lugano, Switzerland
2007* – 1st Eastern Mediterranean Meeting of EAU, Antalya, Turkey
2007 – ESMO International Symposium (EIS) on Immunology, Athens, Greece
2008^P – 23rd Annual Congress, European Association of Urology, Milan, Italy
2008 – Immunology for oncologists, Red Square Seminar, ESO, Moscow
2008 – ASCO 2008 Annual Meeting, Chicago, USA
2008^P – 2d ESMO Educational Conference Lugano, Lugano, Switzerland
2008 – Patient Seminar, ESMO Congress, Stockholm, Sweden
2008^P – 7th International Kidney Cancer Symposium, Chicago, USA
2008^P – World Cancer Congress, UICC, Geneva, Switzerland
2009^P 100th AACR Annual Meeting, Denver, USA
2009^P – ECCO-ESMO congress, Berlin, Germany
2010^P – Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association, Hawaii, USA
2010^P 101th AACR Annual Meeting, Washington, USA
2010 – Fifth European Kidney Cancer Symposium, London, GB
2010^P – ASCO 2010 Annual Meeting, Chicago, USA
2010 – ESMO Congress, Milan, Italy
2010* – C.I.S. Cancer Congress, Almaty, Kazakhstan
2011* – 3d International Congress of Antibodies, Beijing, China
2011^P – 102d AACR Annual Meeting, Orlando, USA
2011* – Eurasian Seminar on Palliative Care & Supportive Therapy, Samara, Russia
2011* – Educational Cancer Convention Lugano “What’s new and what’s true in genitor-urinary oncology”? European School of Oncology, Lugano, Switzerland

2011^{P/discussion} - ECCO-ESMO congress, Stockholm, Sweden
2012^P - ASCO-GU, San Francisco, USA
2012^P - ASCO 2012 Annual Meeting, Chicago, USA
2012 - ESMO Congress, Vienna, Austria
2012^P - 103d AACR Annual Meeting, Chicago, USA
2013 - GU ASCO, Orlando, USA
2013 - Kidney Cancer Association Patient Seminar, Budapest, Hungary
2013^P - 104th AACR Annual Meeting, Washington DC, USA
2013 - 2013 ASCO Annual Meeting, Chicago, USA
2013* - ASCO International Clinical Trials Workshop, Saint-Petersburg, Russia
2013* - EMUC-2013, Marseille, France
2014^P - GU ASCO, San Francisco, USA
2014^P - 105th AACR Annual Meeting, San Diego, USA
2014^P - TAT congress 2014, Washington DC, USA
2014^P - ESMO Congress, Madrid, Spain
2014* - 14th Annual Biotech In Europe Forum For Global Partnering & Investment, Basel, CH
2014^P - ESMO Congress, Madrid, Spain
2014^P - Ninth International Kidney Cancer Symposium, Chicago, USA
2014^P - 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain
2014^P - 2014 San Antonio Breast Cancer Symposium, San Antonio, USA
2015^P - 106th AACR Annual Meeting, Philadelphia, USA
2015* - 8th Annual World Cancer Congress, Beijing, China
2015* - Russian International Kidney Cancer Symposium (RUSSCO-Kidney Cancer Association), Moscow, Russia
2015^P - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, USA
2016^P - GU ASCO, San Francisco, USA
2016^P - 107th AACR Annual Meeting, New Orleans, USA
2016 - 2016 ASCO Annual Meeting, Chicago, USA
2016^P - ESMO Congress, Copenhagen, Denmark
2016^P - 15th International Kidney Cancer Symposium, Miami, USA
2016* - ESMO Asia congress, Singapore
2017^P - 2017 Cancer Survivorship Symposium, San Diego, USA
2017^P - 2017 AACR Annual Meeting, Washington D.C., USA
2017* - Russian International Kidney Cancer Symposium (RUSSCO-Kidney Cancer Association), St. Petersburg, Russia
2017^P - 2017 ASCO Annual Meeting, Chicago, USA
2017^P - ESMO Congress, Madrid, Spain
2017^P - IASLC WCLC 2017, Yokohama, Japan
2018^P - GU ASCO Symposium, San Francisco, USA
2018* - 2018 ASCO Annual Meeting, Chicago, USA
2018* (Late-breaking abstract) - MASCC/ISOO 2018 Annual meeting, Vienna, Austria
2018* - European School of Oncology, Baltic Masterclass in Clinical Oncology, Riga, Latvia
2018^P - ESMO Congress, Munich, Germany
2019^P - GU ASCO Symposium, San Francisco, USA
2019^P - ENDO congress, New Orleans, USA
2019^P - 2019 AACR Annual Meeting, Atlanta, USA
2019* - European School of Oncology, Baltic Masterclass in Clinical Oncology, Minsk, Belarus
2019* - Immunooncology congress, Barcelona, Spain
2019^P - AACR Special Conference on Tumor Immunology and Immunotherapy, Boston, USA
2019^P - ESMO Congress, Barcelona, Spain
2020^P - GI ASCO Symposium, San Francisco, USA
2020^P - GU ASCO Symposium, San Francisco, USA
2020* - ASCO Clinical Trials Session, Faculty Member, online
2021* - ASCO Clinical Trials Session, Faculty Member, online
2021^P - GU ASCO Symposium, virtual meeting, USA
2021* - AACR Annual Meeting, online
2021* - ASCO Clinical Trials Session, Faculty Member, online
2021^P - 2021 ASCO Quality Care Symposium, San Diego, USA

2021* - 2021 AACR Virtual Meeting, online
2022^P - GI ASCO Symposium, San Francisco, USA
2022^P - AACR Annual Meeting, New Orleans, USA
2022^P - International Kidney Cancer Symposium, Austin, USA
2023^P - GI ASCO Symposium, San Francisco, USA
2023 - 2023 ASCO Annual Meeting, Chicago, USA
2023^P - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, USA
2023^P - ESMO Congress, Madrid, Spain
2023^P - EMUC Congress, Marsielle, France
2024^P - GI ASCO Symposium, San Francisco, USA
2024^P - GU ASCO Symposium, San Francisco, USA
2024* - ASCO-BUCARE Bone metastases Webinar, online
2024^P - 2024 ASCO Annual Meeting, Chicago, USA
2024^P - 2024 ASCO Breakthrough, Yokohama, Japan
2024* - 2024 BEST of ASCO, Almaty, Kazakhstan
2024* - 2024 Annual Meeting of Urology, Tripoli, Libya
2024^P - 25th International Kidney Cancer Symposium (IKCS):North America, Louisville, USA
2024^P - ESMO Asia congress, Singapore
2025^P - GU ASCO Symposium, San Francisco, USA

PUBLICATIONS

International Journals

Hirsch index	24
number of citations	2,191
i10-index	37

Tsimafeyeu I, Sultanbaev A, Dubovichenko D, Murzalina M, Volkov A, Orlova R, Utyashev I, Malina G, Gluzman M. Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma. *Explor Target Antitumor Ther.* 2025;6:1002305. <https://doi.org/10.37349/etat.2025.1002305>

Tsimafeyeu I, Gridneva Y, Sultanbaev A, Anzhiganova Y, Gluzman M, Mochalova A, Shkurat A, Israelyan E, Parsadanova E, Murzina Y, Ivanov A, Kalpinskiy A, Stativko O, Petkau V, Karabina E, Keln A, Tovbik N, Safina S, Turganova M, Kopyltsov E, Bragina V, Novikova O, Lebedinets A, Vodolazskiy V, Rummyantsev A, Zukov R, Pokataev I, Orlova R, Volkova M. Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study. *Cancer Med.* 2025 Feb;14(4):e70636.

Tsimafeyeu I, Musayeva G, Mahmudova S, Otkhozoria N, Abbasov B, Kahharov A, Guliyev F. Nivolumab Combined with Chemotherapy in FGFR2 and PD-L1 Co-Expressing Metastatic Gastric Cancer: A Prospective Phase 2 NIVOFGR2 Study. *J Gastrointest Canc* 56, 40 (2025).

Tsimafeyeu I, Chubenko V, Baklanova O, Kalpinskiy A, Safina S, Lebedinets A, Petkau V, Parsadanova E, Turganova M, Shkurat A, Tovbik N, Tkacheva E, Anzhiganova Y, Novikova O, Bragina V, Zukov R, Orlova R. Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study. *Curr Oncol.* 2024 Dec 27;32(1):11.

Tsimafeyeu I, Makhov P, Ovcharenko D, Smith J, Khochenkova Y, Olshanskaya A, Khochenkov D. A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models. *Immuno-oncol Technol.* 2024 Jul 26;23:100725.

Tsimafeyeu, I. Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression. *Med. Sci.* 2024, 12, 48. <https://doi.org/10.3390/medsci12030048>

Tsimafeyeu I, Goutnik V, Shrainer I, Kosyrev V, Bondarenko A, Utyashev I. Intrapleural nivolumab in cancer patients with pleural effusion. *J Cancer Res Ther.* 2024 Apr 1;20(3):1036-1038.

Shatkovskaya O, Kaidarova D, Ongarbayev B, Sagi M, **Tsimafeyeu I.** Five-year overall survival of patients with advanced bladder cancer in Kazakhstan: OSURK registry study. *Am J Clin Exp Urol.* 2023 Dec 15;11(6):542-548.

Tsimafeyeu I and Raskin G (2023) Challenges of FGFR2 Testing in Gastric Cancer. *Oncol. Rev.* 17:11790. doi: 10.3389/or.2023.11790

Zakurdaeva K, **Tsimafeyeu I.** Immunotherapy in cancer patients with chronic hepatitis C viral infection. *J Cancer Res Ther.* 2023 Jul-Sep;19(5):1093-1097. doi: 10.4103/jcrt.jcrt_2095_21.

Tsimafeyeu I, Musaeva G, Utyashev I, Zakurdaeva K, Gerk I, Olshanskaya A, Mahmudova S, Otkhozoria N, Volkova M, Mitin T. Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial. *Kidney Cancer.* 2023 October; 7(1):115-121. doi: 10.3233/KCA-230007.

Tsimafeyeu I, Basin MF, Bratslavsky G. Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments. *World J Urol.* 2023 Jul;41(7):1855-1859. doi: 10.1007/s00345-023-04450-8. Epub 2023 Jun 13.

Tsimafeyeu I, Goutnik V, Shrainer I, Kosyrev V, Bondarenko A, Utyashev I. Multicenter phase 2 study of intrapleural nivolumab in patients with metastatic non-small cell lung cancer and pleural effusion. *Am J Cancer Res.* 2023 Mar 15;13(3):1103-1106.

Tsimafeyeu I, Statsenko G, Vladimirova L, Besova N, Artamonova E, Raskin G, Rykov I, Mochalova A, Utyashev I, Gorbacheva S, Kazey V, Gavrilova E, Dragun N, Moiseyenko V, Tjulandin S. A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer. *Invest New Drugs.* 2023 Mar 13. doi: 10.1007/s10637-023-01340-z. Epub ahead of print.

Tsimafeyeu I, Goutnik V, Shrainer I, Kosyrev V, Bondarenko A, Utyashev I. Multicenter phase 2 study of intrapleural nivolumab in patients with metastatic non-small cell lung cancer and pleural effusion. *Am J Cancer Res.* 2023 Mar 15;13(3):1103-1106. PMID: 37034218; PMCID: PMC10077040.

Tsimafeyeu I, Volkova M, Alekseeva G, Berkut M, Nosov A, Myslevtsev I, Andrianov A, Semenov A, Borisov P, Zukov R, Goutnik V, Savchuk S, Dengina N, Mitin T. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies. *J Hematol Oncol.* 2021 Nov 13;14(1):192. doi: 10.1186/s13045-021-01205-z.

Tsimafeyeu I, Temper M. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. *Gastrointestinal Tumors*, [published online ahead of print, July 2021]. doi: 10.1159/000517258

Tsimafeyeu I. Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma. *Kidney Cancer* 2021: 63 – 71.

- Volkova M, **Tsimafeyeu I**, Olshanskaya A, Khochenkova Y, Solomko E, Ashuba S, Matveev V, Khochenkov D. Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma. *Am J Clin Exp Urol*. 2021 Feb 15;9(1):65-72.
- Dengina N, Chernykh M, Degnin C, Chen Y, **Tsimafeyeu I**, Karaseva VV, Tjulandin S, Laktionov K, Thomas CR Jr, Mitin T. Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia. *J Cancer Educ*. 2021 Feb 2. doi: 10.1007/s13187-021-01966-8.
- Tsimafeyeu I**, Tishova Y, Zukov R, Borisov P, Bondarenko A, Zakurdaeva K. Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES. *Am J Clin Oncol*. 2021 Apr 1;44(4):137-142.
- Tsimafeyeu I**, Shatkovskaya O, Krasny S, Nurgaliev N, Varlamov I, Petkau V, Safina S, Zukov R, Mazhbich M, Statsenko G, Varlamov S, Novikova O, Zaitsev I, Moiseyev P, Rolevich A, Evmenenko A, Popova I, Kaidarova D, Vladimirova L. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. *Cancer Rep (Hoboken)*. 2021 Jun;4(3):e1331.
- Volkova M, **Tsimafeyeu I**, Olshanskaya A, Khochenkova Y, Solomko E, Ashuba S, Khochenkov D, Matveev V. Expression of growth factors and their receptors in the primary renal cell carcinoma: new data and review. *Cent European J Urol*. 2020; 73: 466-475.
- Imyanitov EN, Ivantsov AO, **Tsimafeyeu IV**. Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. *Front Oncol*. 2020 Sep 30;10:549198. doi: 10.3389/fonc.2020.549198. PMID: 33102215; PMCID: PMC7554524.
- Tsimafeyeu I**, Alekseeva G, Berkut M, Nosov A, Myslevtsev I, Andrianov A, Semenov A, Borisov P, Zukov R, Goutnik V, Savchuk S, Volkova M, Mukhina M. COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation. *Clin Genitourin Cancer*. 2020 Jul 16:S1558-7673(20)30167-1.
- Tsimafeyeu I**, Volkova M. Management of Patients with Renal Cell Carcinoma during Coronavirus Pandemic: Proposed Algorithm in Russia. *Clin Oncol*. 2020; 5:1707.
- Byakhova MM, Zavalishina LE, Andreeva YY, Tyulyandin SA, **Tsimafeyeu IV**, Imyanitov EN, Savelov NA, Demidova IA, Kekeyeva TV, Mueva NM, Frank GA. Epidemiologiya i diagnostika mutatsii v gene ALK u patsientov s nemelkokletochnym rakom legkogo v Moskovskoi oblasti [Epidemiology and diagnosis of mutations in the ALK gene in patients with non-small cell lung cancer in the Moscow region]. *Arkh Patol*. 2020;82(3):18-23. Russian.
- Mitin T, Dengina N, Chernykh M, Usyckin S, Gladkov O, Degnin C, Chen Y, Nosov D, **Tsimafeyeu I**, Thomas CR Jr, Tjulandin S. Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise [published online ahead of print, 2020 Mar 4]. *J Cancer Educ*. 2020;10.1007/s13187-020-01728-y.
- Tsimafeyeu I**, Imyanitov E, Zavalishina L, Raskin G, Povilaitite P, Savelov N, Kharitonova E, Rumyantsev A, Pugach I, Andreeva Y, Petrov A, Frank G, Tjulandin S. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. *Sci Rep*. 2020;10(1):3928.

Tsimafeyeu I, Gafanov R, Protsenko S, Semenova A, Oganessian A, Nurgaliyev N, Krasny S, Bondarenko A, Safina S, Zakurdaeva K. Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. *Cancer Immunol Immunother*. 2020;69(6):983-988.

Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, **Tsimafeyeu I**, Thomas CR Jr, Tjulandin S, Likhacheva A. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise. *J Cancer Educ*. 2020;35(1):105-111.

Tsimafeyeu I, Volkova M, Olshanskaia A, Raskin G, Aschuba S, Khochenkova Y, Bondarenko A, Khochenkov D. Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors. *Oncology*. 2020;98(4):252-258.

Dengina N, Mitin T, Gamayunov S, Safina S, Kreinina Y, **Tsimafeyeu I**. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. *ESMO Open* 2019;4:e000535. doi:10.1136/esmoopen-2019-000535

Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A, Khalimov A, Karabina E, Shikina V, Abdelgafur A, Statsenko G, Titova I, Isaichikov D, Makarnyaeva G, Mordovskiy A, Barkovskaya O, Smirnov A, Gikalo M, Savelov N, Kosov D, Imyanitov E, Demidova I, Tjulandin S. Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study. *J Glob Oncol*. 2019 May;5:1-7.

Tsimafeyeu I, Borisov P, Abdelgafur A, Leonenkov R, Novikova O, Guseva I, Demchenkova M, Mikhailova N, Semenov A, Yurmazov Z, Sivunova I, Ramazanov M, Gamayunov S, Kosov D, Bratslavsky G. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. *Target Oncol*. 2019 Feb;14(1):33-38.

Tsimafeyeu I, Tjulandin S. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma. *BJU Int*. 2019 Apr;123(4):563-565.

Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, **Tsimafeyeu I**, Thomas CR Jr, Tjulandin S, Likhacheva A. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise. *J Cancer Educ*. 2018 Nov 22. doi: 10.1007/s13187-018-1447-0. [Epub ahead of print]

Tsimafeyeu I, Leonenko V, Kuznetsov V, Semenkova E, Bondarenko A, Demidov L. Paraneoplastic vasculitis in patients with metastatic renal cell carcinoma. *Cancer Reports*. 2018;e1142. <https://doi.org/10.1002/cnr2.1142>

Zavalishina L, **Tsimafeyeu I**, Povilaitite P, Raskin G, Andreeva Y, Petrov A, Kharitonova E, Rumyantsev A, Pugach I, Frank G, Tjulandin S. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. *Virchows Arch*. December 2018, Volume 473, Issue 6, pp 719–724.

Tsimafeyeu I. Cytoreductive nephrectomy would not be required in intermediate and poor risk patients with metastatic renal cell carcinoma cancer. *Clin Oncol*. 2018;3:1502.

McClelland S 3rd, Chernykh M, Dengina N, Gillespie EF, Likhacheva A, Usyckin S, Pankratov A, Kharitonova E, Egorova Y, **Tsimafeyeu I**, Tjulandin S, Thomas CR Jr, Mitin T. Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia. *J Cancer Educ*. 2018 Jun 25. doi: 10.1007/s13187-018-1388-7.

Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R, Petkau V, Mazhbich M, Statsenko G, Safina S, Zaitsev I, Sakaeva D, Popov A, Borisov P, Vladimirova L. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. *Clin Genitourin Cancer*. 2017 Dec;15(6):e1069-e1072.

Dengina N, **Tsimafeyeu I**, Mitin T. Current Role of Radiotherapy for Renal-Cell Carcinoma: Review. *Clin Genitourin Cancer*. 2017 Apr;15(2):183-187.

Tyulyandina A, Harrison D, Yin W, Stepanova E, Kochenkov D, Solomko E, Peretolchina N, Daeyaert F, Joos JB, Van Aken K, Byakhov M, Gavrilova E, Tjulandin S, **Tsimafeyeu I**. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies. *Invest New Drugs*. 2017 Apr;35(2):127-133.

Tsimafeyeu I, Khasanova A, Stepanova E, Gordiev M, Khochenkov D, Naumova A, Varlamov I, Snegovoy A, Demidov L. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. *Clin Transl Oncol*. 2017 Feb;19(2):265-268.

Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, Novikova I, Samuilenkova O, Tiurin V, Ulianova E, **Tsimafeyeu I**, Tjulandin S. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. *Lung Cancer*. 2017 Jan;103:17-23.

Tsimafeyeu I. Management of non-clear cell renal cell carcinoma: Current approaches. *Urol Oncol*. 2017 Jan;35(1):5-13.

Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, Kekeyeva TV, Moliaka YK, Gervas PA, Kozhemyako VB, Vodolazhskiy DI, Sergeyeva LA, Fattakhova DU, Iyevleva AG, Mitiushkina NV, Kuligina ES, Barinov AA, Mommaeva MS, Aleksakhina SN, **Tsimafeyeu IV**, Tjulandin SA. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. *Mol Diagn Ther*. 2016 Aug;20(4):401-406.

Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Kochenkov D, Joos JB, Solomko E, Van Aken K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. *Eur J Cancer*. 2016 Jul;61:20-8.

Tsimafeyeu I, Daeyaert F, Joos JB, Van Aken K, Ludes-Meyers J, Byakhov M, Tjulandin S. Molecular modeling, de novo design and synthesis of a novel, extracellular binding fibroblast growth factor receptor 2 inhibitor alofanib (RPT835). *Med Chem*. 2016;12(4):303-17.

Tsimafeyeu I. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease. *J Can Res Ther* 2015;11:920-2.

Tsimafeyeu I, Bratslavsky G. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma. *Oncology*. 2015;88(6):321-31. doi: 10.1159/000370118.

Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, Manzuk L. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. *Target Oncol*. 2015 Sep;10(3):423-7.

Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, ... **Tsimafeyeu I**, et al. Challenges to effective cancer control in China, India, and Russia. *Lancet Oncol* 2014; 15: 489–538.

Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. *Invest New Drugs* (2013) 31:1436–1443.

Tsimafeyeu I, Zart JS, Chung B. Cytorreductive radiofrequency ablation in patients with metastatic renal cell carcinoma with small primary tumours treated with sunitinib or interferon- α . *BJU Int*. 2013 Jul;112(1):32-8.

Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Galchenko V, Sinelnikov I, Naidzionak U. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Capecitabine in Patients With Non-Clear Cell Metastatic Renal Cell Carcinoma. *Am J Clin Oncol*. 2012 Jun;35(3):251-4.

I. Tsimafeyeu, L. Demidov, E. Stepanova, N. Wynn and H. Ta. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. *Scand J Urol Nephrol*. 2011 Apr;45(3):190-5. doi: 10.3109/00365599.2011.552436.

Tsimafeyeu I, Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. *J Cancer Res Ther*. 2010 Oct-Dec;6(4):575-7. doi: 10.4103/0973-1482.77084.

Tsimafeyeu I, Aksel E. Renal Cell Carcinoma in the Russian Federation in 2008. *Malign Tumours* 2010;1:1-4.

Tsimafeyeu I, Demidov L, Kharkevich G, Petenko N, Volkova M, et al. Granulocyte-Macrophage Colony-Stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-Risk Renal Cell Carcinoma. *J Cancer Sci Ther* 2010;2:157-159

I. Tsimafeyeu, L. Demidov, A. Madzhuga, O. Somonova, A. Yelizarova. Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. *J Exp Clin Cancer Res*. 2009 Mar 2;28:30. doi: 10.1186/1756-9966-28-30.

Russian Journals

Tsimafeyeu I.V., Baklanova O.V., Chubenko V.A., Kalpinskiy A.S., Safina S.Z., Lebedinets A.A., Petkau V.V., Olshanskaya A.S., Myslevtsev I.V., Zukov R.A. Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study. *Malignant tumours*. 2024;14(4):9-17. (In Russ.) <https://doi.org/10.18027/2224-5057-2024-032>

Raskin GA, Mukhina MS, Kravtsova ED, **Tsimafeyeu IV**, Tyulandin SA, Belyak NP, Kleshchev MA, Orlova RV. Izuchenie statusa FGFR2 pri rake zheludka metodami immunogistokhimii i flyuorestsentnoi gibridizatsii in situ [Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization]. *Arkh Patol*. 2023;85(3):40-45. Russian. doi: 10.17116/patol20238503140. PMID: 37272439.

Tsimafeyeu IV, Zukov RA, Petkau VV, Gamayunov SV, Plokhotenko IV, Kiselev NM, Utyashev IA, Gordon KB, Gulidov IA, Statsenko GB, Vladimirova LYu. Overall survival of patients with metastatic esophageal cancer: Russian multicenter registry study. *Voprosy Onkologii*. 2023;69(1):82-88. doi: 10.37469/0507-3758-2023-69-1-82-88

Volkova M.I., Olshanskaya A.S., **Tsimafeyeu I.V.**, Vashakmadze N.L., Khochenkova Y.A., Solomko E.S., Ashuba S.A., Khochenkov D.A., Matveev V.B. Expression of growth factors and tyrosine kinase receptors in the primary tumor and tumor thrombus cells in patients with renal cell carcinoma. *Cancer Urology*. 2020;16(1):17-26. (In Russ.).

Zavalishina L.E., Povilaitite P.E., Savelov N.A., Andreeva Y.Y., Petrov A.V., Raskin G.A., Kharitonova E.A., Pugach I.M., Rumyantsev A.A., Frank G.A., Imyanitov E.N., **Tsimafeyeu I.V.**, Tjulandin S.A.

Comparison of immunohistochemical tests in the CLOVER study by Russian society of clinical oncology. *Malignant tumours*. 2019;9(4):25-31. (In Russ.).

Volkova M.I., Olshanskaya A.S., Khochenkov D.A., Ashuba S.A., Khochenkova Y.A., **Tsimafeyeu I.V.** Expression of Receptor Tyrosine Kinases on Peripheral Blood Lymphocyte Subpopulations in Patients with Renal Cell Carcinoma and Healthy Volunteers. *Malignant tumours*. 2019;9(4):18-24. (In Russ.).

Tsimafeyeu I. Systemic therapy for advanced kidney cancer. *Practical Oncology*. 2019;20(2):113-122.

Safina S.Z., Varlamov S.A., Snegovoy A.V., Varlamov I.S., Gurina L.I., Manzuk L.V., **Tsimafeyeu I.V.** Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progression on bevacizumab: a prospective multicenter study CRAD001LRU02T. *Cancer Urology*. 2017;13(4):40-44. (In Russ.)

Tsimafeyeu I.V. Sunitinib:10 years after approval for the therapy of metastatic renal cell carcinoma. *Vopr oncol* 2016;6:741-752.

Tsimafeyeu I.V. Current treatment approach to non-clear cell renal carcinoma. *Cancer Urology*. 2015;11(4):24-33. (In Russ.) DOI:10.17650/1726-9776-2015-11-4-24-33

Porta C, **Tsimafeyeu IV.** Targeted therapy for metastatic renal cell carcinoma. *Sovremennaya onkologiya*. 2014;16(3):75-80.

I. Tsimafeyeu. Fibroblast growth factor receptor 1 as target for therapy of renal cell carcinoma. *Current Oncology*, Vol.15 №3 (2013), pp. 56-62.

I. Tsimafeyeu, L. Demidov, N. Petenko. Sunitinib maleate in renal cell carcinoma patients with poor prognosis: Russian study. *J Voprosy onkologii*, 2011(1)

I. Tsimafeyeu. First-line treatment of metastatic renal cell carcinoma. *J Pharmateca*. 2010;6:46-49

I. Tsimafeyeu, L. Demidov Paraneoplastic vasculitis in patients with metastatic renal cell carcinoma. *J Vrach*. 2010;6:18-20

I. Tsimafeyeu, L. Demidov, G. Kharkevich. Analogues of Pirimidine in combination with cytokines as a second line therapy for rapidly progressive metastatic renal cancer. *J. N.N. Blokhin Russian Cancer Research Center*. 2007;18:61-65

I. Tsimafeyeu, A. Madzhuga, L. Demidov, O. Somonova et al. Is hypercoagulation a predictor influencing the efficacy of immunotherapy for metastatic renal cancer? *J. Oncourology*, 2007;1: 30-32

I. Tsimafeyeu, L. Demidov. Renal cell carcinoma: evolution of the treatment approaches. *J. Vrach*, 2007;10:84-87

L. Demidov, G. Kharkevich, **I. Tsimafeyeu**, I. Markina et al. Low doses of Interleukin-2 in combination with Interferon- α and 5-Fluorouracil for metastatic renal cell carcinoma. Preliminary results of randomized trial. *J. Oncourology*, 2006;4:15-18

L. Demidov, G. Kharkevich, **I. Tsimafeyeu**. GM-CSF in treatment of skin melanoma and renal cell carcinoma. *J. Cathedra medicinae*, 2005;5:17,42-49.

L. Demidov, G. Kharkevich, **I. Tsimafeyeu**. Roncoleukin, Reaferon and Aranoza for treatment of Advanced Melanoma. *Russian Journal of Biotherapy*, 2004; 2:67-68.

L. Demidov, E. Semenkova, G. Kharkevich, **I. Tsimafeyeu**. Management of paraneoplastic vasculitis by IL-2 in patient with metastatic renal cell carcinoma. *J. Therapeutic Archives*, 2004; 10:23-25.

I. Tsimafeyeu, G. Kharkevich, L. Demidov. Efficacy of adjuvant immunotherapy with GM-CSF in II stage melanoma patients. *RSMU Bulletin*, 2003;2:12-15.

L. Demidov, G. Kharkevich, **I. Tsimafeyeu**. Success and failure of cytokine therapy in oncology. Journal of Practical Oncology, 2003;4:3;140-147.

I. Tsimafeyeu, T. Yanushkevich. Proteinuria in cancer patients. Journal of Pavlov State Medical University of Saint Petersburg, 2002; 1: 18-21.

L. Demidov, G. Kharkevich, **I. Tsimafeyeu**. Adjuvant immunotherapy of stage II melanoma patients with low dose of rGM-CSF: dynamics of immunological and hematological values. Russian Journal of Biotherapy, 2002; 4:49-53.

Books:

I. Tsimafeyeu

Editor-in-Chief, Handbook "Kidney cancer 2020" (Russia and C.I.S.)

I. Tsimafeyeu

Editor-in-Chief, Handbook "Kidney cancer 2017" (Russia and C.I.S.)

I. Tsimafeyeu

Editor-in-Chief, Handbook "Kidney cancer 2016" (Russia and C.I.S.)

I. Tsimafeyeu

Editor-in-Chief, Handbook "Kidney cancer 2015" (Russia and C.I.S.)

I. Tsimafeyeu

Editor-in-Chief, Handbook "Kidney cancer 2012" (Russia and C.I.S.)

I. Tsimafeyeu

Editor-in-Chief, "Hybrid" Guidelines for kidney cancer 2011 (Russia and C.I.S.)

I. Tsimafeyeu, V. Nechushkina

Editor-in-Chief, Russian Edition, "Kidney Cancer" 2010 v.1 NCCN guidelines

I. Tsimafeyeu

Editor-in-Chief, Russian Edition, Kidney Cancer Association book "We have Kidney Cancer" 2010

I. Tsimafeyeu

Textbook for kidney cancer patients, Second Edition, Moscow, 2009, 74 pp.

ISBN 978-5-9901560-1-3

I. Tsimafeyeu

Editor-in-Chief, Russian Edition, "Kidney Cancer" 2009 v.1 NCCN guidelines

I. Tsimafeyeu

Textbook for kidney cancer patients, Moscow, 2008, 38 pp.

ISBN 978-5-9901560-1-2

L. Demidov, **I. Tsimafeyeu**, G. Kharkevich

"Introduction to Tumor Biotherapy", Moscow, 2006, 64 pp.